Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy (vol 117, pg 858, 2001)

被引：0
作者：
Pellet, C
Chevret, S
Blum, L
Gauville, C
Hurault, M
Blanchard, G
Agbalika, F
Lascoux, C
Ponscarme, D
Morel, P
Calvo, F
Lebbe, C
机构：
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2002年 / 118卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：741 / 741
页数：1
相关论文
共 50 条
  • [41] NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma
    Sirianni, MC
    Vincenzi, L
    Topino, S
    Giovannetti, A
    Mazzetta, F
    Libi, F
    Scaramuzzi, D
    Andreoni, M
    Pinter, E
    Baccarini, S
    Rezza, G
    Monini, P
    Ensoli, B
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2002, 32 (10) : 2711 - 2720
  • [42] Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)
    Pulido, F
    Arribas, JR
    Miró, JM
    Costa, MA
    Gonález, J
    Rubio, R
    Peña, JM
    Torralba, M
    Lonca, M
    Lorenzo, A
    Cepeda, C
    Vázquez, JJ
    Gatell, JM
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (04) : 343 - 350
  • [43] Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy
    Leitch, H
    Trudeau, M
    Routy, JP
    HIV CLINICAL TRIALS, 2003, 4 (02): : 107 - 114
  • [44] Highly Active Antiretroviral Therapy Alone is an Effective Treatment for Lymphadenopathic Kaposi Sarcoma Demonstrated by a Clinical and F-18 FDG Positron Emission Tomography/Computed Tomography Response
    Mankia, S. K.
    Miller, R. F.
    Edwards, S. G.
    Ramsay, A.
    Lee, S. M.
    CLINICAL ONCOLOGY, 2012, 24 (04) : 309 - 311
  • [45] Prognosis of patients with AIDS-associated Kaposi's sarcoma receiving antiretroviral therapy +/- chemotherapy in Kwazulu-Natal, South Africa: an analysis of 1-yr survival data from NCT00380770
    TS Uldrick
    A Mosam
    F Shaik
    G Friedland
    D Skadden
    JP Jordaan
    J Aboobaker
    HM Coovadia
    Infectious Agents and Cancer, 4 (Suppl 2)
  • [46] HIV-associated Multicentric Castleman's disease (MCD) may present in the context of immune reconstitution (IR); highly active antiretroviral therapy (HAART) alone can modify clinical response and is associated with radiological response and suppression of Kaposi Sarcoma Herpes Virus (KSHV) viraemia
    Chilton, D. N.
    Raja, F.
    Lee, S. M.
    Paul, J.
    Ramsay, A.
    Millers, R. F.
    Edwards, S. G.
    HIV MEDICINE, 2009, 10 : 49 - 49
  • [47] As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial
    Hosseinipour, Mina C.
    Kang, Minhee
    Krown, Susan E.
    Bukuru, Aggrey
    Umbleja, Triin
    Martin, Jeffrey N.
    Orem, Jackson
    Godfrey, Catherine
    Hoagland, Brenda
    Mwelase, Noluthando
    Langat, Deborah
    Nyirenda, Mulinda
    MacRae, John
    Borok, Margaret
    Samaneka, Wadzanai
    Moses, Agnes
    Mngqbisa, Rosie
    Busakhala, Naftali
    Martinez-Maza, Otoniel
    Ambinder, Richard
    Dittmer, Dirk P.
    Nokta, Mostafa
    Campbell, Thomas B.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (02) : 251 - 260
  • [48] Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy (vol 31, pg 3668, 2013)
    Mena, Guillermo
    Garcia-Basteiro, Alberto L.
    Llupia, Anna
    Diez, Consolacion
    Costa, Josep
    Gatell, Josep-Maria
    Garcia, Felipe
    Bayas, Jose-Maria
    VACCINE, 2015, 33 (10) : 1297 - 1297
  • [49] AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): A model of the interplay of the immune system, virus, and cancer. "On the offensive - The Trojan horse is being destroyed " - Part A: Kaposi's sarcoma
    Cheung, TW
    CANCER INVESTIGATION, 2004, 22 (05) : 774 - 786
  • [50] Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: From the AIDS malignancy consortium and IM862 study team
    Noy, A
    Scadden, DT
    Lee, J
    Dezube, BJ
    Aboulafia, D
    Tulpule, A
    Walmsley, S
    Gill, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) : 990 - 998
12345